News

Real-World Evidence from McKesson Supports First-Ever FDA Approval for Metastatic Merkel Cell Carcinoma Drug

May 16, 2018

Study Wins the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes

The Woodlands, Texas (May 16, 2018) —  A powerful, real-world evidence study designed by McKesson Specialty Health for its biopharma partner played a key role in the Food and Drug Administration’s (FDA) approval for first-line indication for a rare disease. Recently “Merkel Cell Carcinoma Observational Study for Historic Comparison” received the 2018 Clinical and Research Excellence (CARE) Award for Best in Health Economics and Outcomes Research, recognizing how data research supports true innovation in oncology care.

The award acknowledges excellence in health economics and outcomes research (HEOR), a strategic focus for the company, and was announced at an award ceremony with organizers Pharma Intelligence, biopharma companies, researchers, and providers last month in Boston.

Read More

Texas Oncology Receives 2018 PBMI Excellence Award for Care Management Strategies

May 7, 2018

Industry Recognition Highlights Texas Oncology’s  Integrated Pharmacy Approach to Attain Better Patient Outcomes and Lower Costs

DALLAS (May 7, 2018) — Texas Oncology, a practice in The US Oncology Network (The Network), received a 2018 Excellence Award from Pharmacy Benefit Management Institute® (PBMI) for its Medically Integrated Pharmacy Management (MIPM) approach to achieve better results in cancer care. The MIPM model includes a team of board-certified oncologists, as well as other healthcare professionals, to deliver patient-focused solutions that drive industry-leading outcomes and contain costs.

Read More

Virginia Cancer Specialists and The US Oncology Network Welcome Breast Surgeon Dr. Hernan Vargas

March 12, 2018

Renowned breast surgeon joins practice with more than two decades of experience, expanding the service offering to more patients

Fairfax, Va. (March 12, 2018) Virginia Cancer Specialists (VCS) announced that Hernan Vargas, MD, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.

Read More

Consultants in Medical Oncology and Hematology Joins The US Oncology Network, Enhancing Its Ability to Deliver High-Quality Care throughout the Greater Philadelphia Area

January 18, 2018

Practice increases clinical trial and advanced treatment options while gaining access to resources that improve operational efficiencies

Philadelphia, Pa. (January 18, 2018) – Consultants in Medical Oncology and Hematology (CMOH), a premier provider of comprehensive medical oncology services throughout the Philadelphia region for nearly 30 years and a national leader in the development of patient and physician-focused value-based cancer care delivery models, has joined The US Oncology Network (The Network). The Network is the largest organization of its kind comprised of community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care.

Read More

iKnowMed EHR and iKnowMed Generation 2 EHR Receive 2015 ONC-ACB Certification

January 5, 2018

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System

Read More

McKesson Specialty Health and US Oncology Research Announce Schedule of Presentations at the 2017 American Society of Hematology Annual Meeting and Exposition

December 4, 2017

19 abstracts on clinical research conducted by top affiliated investigators are scheduled for presentation

The Woodlands, Texas (December 4, 2017) – At the 59th American Society of Hematology Annual Meeting and Exposition (ASH), leading investigators from The US Oncology Network and US Oncology Research will showcase detailed findings from 19 studies (four orals, 14 poster presentations and one e-publication) covering topics such as multiple myeloma, chronic lymphocytic leukemia, myeloproliferative neoplasms and more. The 59th ASH Annual Meeting, a premier scientific event in malignant and non-malignant hematology, will be held December 9-12 in Atlanta.

Read More

Virginia Cancer Specialists and The US Oncology Network Welcome Dr. Stephanie Akbari

November 28, 2017

Dr. Akbari, a pioneer in breast cancer surgery, brings new line of treatment services to the clinic

Fairfax, Va. (November 28, 2017) Virginia Cancer Specialists (VCS) announced that Stephanie Akbari, MD, FACS, has joined the practice. VCS, a practice in The US Oncology Network, is a premier cancer care and research center in Northern Virginia with more than 40 years of service to patients.

Read More

Frederick Oncology & Hematology Associates Joins Maryland Oncology Hematology and The US Oncology Network

November 3, 2017

Affiliation enhances care at both practices, expanding Maryland Oncology Hematology’s services into the Baltimore–Washington Metropolitan Area

Read More

US Oncology Research Annual Science Forum Focuses on Advances in Clinical Research, Enabling Promising New Treatments for Patients in the Community Setting

November 2, 2017

Organization celebrates enrolling 70,000 patients to clinical trials, contributing to more than 70 FDA cancer therapy approvals

Read More

Southern Cancer Center is Global Leader in Kidney Cancer Clinical Trial

September 19, 2017

Mobile, Ala. (September 19, 2017) - Southern Cancer Center (SCC), a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.

This phase 3 clinical trial will look at various investigational combination therapies including an immune checkpoint inhibitor. This is an important trial to gain information on previously untreated advanced or metastatic renal cell carcinoma (RCC).

Read More

US Oncology Research plays an important role in the clinical development for NERLYNX (neratinib) tablets

September 12, 2017

NERLYNXTM is a new treatment option for early-stage HER2+ breast cancer patients following adjuvant trastuzumab-based therapy in the extended adjuvant setting

The Woodlands, Texas (September 12, 2017) — Early-stage breast cancer patients with HER2-positive tumors now have a promising new anti-HER2 treatment option in the extended adjuvant setting, thanks in large part to the efforts and expertise of US Oncology Research and McKesson Specialty Health. US Oncology Research is the pioneering research arm of The US Oncology Network and is supported by McKesson Specialty Health. US Oncology Research played an important pivotal role supporting the drug’s manufacturer, Puma Biotechnology, Inc., through the clinical trial, ExteNET that led to approval by the U.S. Food and Drug Administration (FDA) on July 17, 2017.

Read More

US Oncology Research and Epizyme Establish Collaboration to Identify Non-Hodgkin Lymphoma Patients with EZH2 Mutations

August 1, 2017

Eligible Patients to be Directed to Epizyme’s Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma

THE WOODLANDS, Texas and CAMBRIDGE, Mass. (August 1, 2017) - Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, and US Oncology Research, one of the nation’s largest networks of independent, community-based oncology practices dedicated to advancing high-quality treatments through clinical trials, today announced a collaboration to screen and identify relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) patients with EZH2 mutations. Once identified, eligible candidates will be directed to Epizyme’s ongoing Phase 2 clinical trial of tazemetostat, the Company’s first-in-class EZH2 inhibitor, as a single-agent treatment for relapsed or refractory patients with FL or DLBCL.

Read More

The US Oncology Network Hosts Second Annual Boot Camp Focusing on New Value-Based Care and Payment Models

June 23, 2017

Intensive workshop provided resources, expertise to help practices succeed with the Oncology Care Model, MIPS and other alternative payment programs

Read More

McKesson Specialty Health and The US Oncology Network Expand Agreement with The National Comprehensive Cancer Network, Adding New Disease States to Value Pathways

June 14, 2017

Expanded agreement enhances Value Pathways, providing physicians access to the most recent evidence available for five additional disease states

Read More

Arizona Oncology Opens State-of-the-Art Cancer Treatment Center at ASU Research Park

June 13, 2017

New facility developed by Ryan Companies US, Inc. offers leading-edge cancer care to growing East Valley region

Tempe, Ariz. (June 13, 2017) — Arizona Oncology’s new state-of-the-art cancer treatment center, located at the Arizona State University Research Park (ASURP), is now open and offering the latest cancer treatment services available to patients in Phoenix and the East Valley. The new center, developed and built by Ryan Companies US, Inc., offers integrated, high-quality care to diagnose and treat cancer. Patient services include medical, gynecologic and radiation oncology, hematology, advanced diagnostics including PET/CT imaging, supportive care services, and clinical trials. The practice is also offering the latest treatment options for patients, including immuno-oncology, bio markers, and targeted therapies.

Read More

Virginia Cancer Specialists Opens New Research Facility for Phase I Clinical Trials, Leading the Region in Advanced Cancer Research

June 8, 2017

New clinic enhances world-class research program by strengthening Phase I capabilities

Fairfax, Va. (June 8, 2017) There is good news today for patients in Northern Virginia who are battling cancer, as well as those who may face the disease in the future. Virginia Cancer Specialists (VCS), Northern Virginia’s premier cancer care and research center with more than 40 years of service to patients and a practice in The US Oncology Network, has opened a new state-of-the-art research clinic in Fairfax, Virginia dedicated exclusively to Phase I clinical trials. A ribbon cutting ceremony was held May 24 to officially mark the opening.

Read More

Community Oncologists from The US Oncology Network and US Oncology Research Share Meaningful Research and Visionary Thinking During American Society of Clinical Oncology Annual Meeting

May 31, 2017

Approximately 40 abstracts accepted for presentation, highlighting the importance of community-based cancer research in developing new and novel cancer fighting therapies in areas like hematology, breast cancer, and immuno-oncology

Debra Patt, MD, MBA, MPH, to speak during an Educational Session on creating an informatics-driven oncology practice

Read More

McKesson Specialty Health Selected by TESARO to provide ZEJULA (niraparib), Approved for the Treatment of Recurrent Ovarian Cancer

May 12, 2017

The Woodlands, Texas (May 12, 2017)McKesson Specialty Health, a division of McKesson Corporation that works together with stakeholders across the healthcare delivery system to preserve and strengthen specialty care, has played a significant role in the recent approval of ZEJULATM (niraparib). Approximately ten practices affiliated with US Oncology Research, one of the largest community-based oncology research programs in the United States supported by McKesson Specialty Health, participated in the clinical trial that led to approval by the U.S. Food and Drug Administration (FDA) on March 27, 2017. ZEJULA marks the 66th FDA approval in which US Oncology Research has contributed.

Read More

Thought Leaders from McKesson Specialty Health and The US Oncology Network Are Key Presenters at the 2017 Community Oncology Conference

April 27, 2017

Presentations will focus on innovative solutions for community oncology success and cancer care delivery in today’s challenging environment

Read More

US Oncology Research Enrolls 2,900 Patients in Leading-Edge Clinical Trials in Twelve Months

April 25, 2017

Program reaches recruitment milestone while bringing novel treatments to community cancer centers

The Woodlands, Texas (April 25, 2017)US Oncology Research, one of the largest community-based oncology research programs in the United States, enrolled more than 2,900 subjects into clinical trials during the fiscal year ended March 31, 2017. The participation of these patients in leading-edge oncology trials for a wide range of cancer types contributed to eight cancer therapies receiving FDA approvals, making promising new treatments available to cancer patients across the nation. Contributing to so many FDA approvals in one fiscal year is unprecedented for US Oncology Research and demonstrates the organization’s strong ongoing commitment to play a vital role in understanding cancer and identifying effective therapies. In total, US Oncology Research has enrolled more than 66,000 patients into clinical trials since its inception in 1992.

Read More

Pages